To the Editor We read with interest the recent article by Guenezan et al, "Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial," published in JAMA Otolaryngology–Head and Neck Surgery on the use of nasal and oral application of 1% povidone iodine (PVP-I) solution in nonadmitted patients with COVID-19. We congratulate the authors for publishing this highly relevant clinical data pertaining to the ongoing pandemic. Despite the rollout of safe vaccination, the final outcome of SARS-CoV-2 remains to be seen. Until the definitive data emerges (possibly even beyond then), the importance of preventive strategies cannot be overemphasized. The wide availability and antimicrobial spectrum (including virucidal properties against SARS-CoV-2 demonstrated i n the in vitro studies) make it an attractive agent for limiting the infection spread. The current pilot study provides important preliminary data and may boost larger-scale studies to reach more definitive conclusions. However, for the readers' benefit and possible optimization of future study designs, we would like to gain more clarity regarding some of the facts presented in the study.
No comments:
Post a Comment